Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Biodistribution and dosimetry results form a phase III prospectively randomized controlled trial of zevalin radioimmunotherapy for low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Wiseman GA, White CA, Sparks RB, Erwin WD, Pololoff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR. Biodistribution and dosimetry results form a phase III prospectively randomized controlled trial of zevalin radioimmunotherapy for low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology Hematology. 2001; 39:181-194..


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.